Phase 2 Psoriasis Trial, Recruiting NCT07233291 Sponsor: Ahmed Ibrahim Condition: Psoriasis
Back to Psoriasis

Phase 2 Psoriasis Trial, Recruiting

NCT07233291
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who have psoriasis and for whom a whole-body (systemic) treatment has been recommended by their doctor
  • People diagnosed with chronic stable plaque psoriasis (a long-term, steady form of psoriasis that causes raised, scaly patches on the skin)
  • People who have not used any whole-body (systemic) psoriasis treatment in the past 2 months, or who have never used one before
  • People who are willing and able to use reliable contraception throughout the study period

Who may not be able to join:

  • Women who are pregnant or breastfeeding, or women who could become pregnant but are not using an effective form of contraception
  • People under 18 years of age
  • People currently using other whole-body (systemic) psoriasis treatments, such as Acitretin or biologic medicines
  • People who have used any whole-body (systemic) psoriasis treatment within the last 2 months
  • People taking certain medicines that affect how the body processes drugs (specifically medicines that interact with liver enzymes called CYP3A4 and CYP1A) (confirm with trial site)
  • People with serious conditions affecting organs such as the liver — note that people with COPD (a lung condition) may still be considered
  • People with a known allergy or sensitivity to the study drug roflumilast or any of its ingredients
  • People using a specific contraceptive pill containing gestodene and ethinylestradiol
  • People who, in the clinical team's assessment, may be unable to reliably follow the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Abeer Mohamed Elkholy, MD Dermatology, Faculity of Medicine, Mansoura University

Phone: +201060291029

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ahmed Ibrahim
Registry
ClinicalTrials.gov
Start date
20 August 2025
Est. completion
28 February 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Mean change in Psoriasis Area and Severity Index (PASI) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov